New depression pill shows promise in early trial

NCT ID NCT03726658

Completed Symptom relief Sponsor: Syndeio Biosciences, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called AGN-241751 in 226 adults with major depressive disorder. Participants received either the drug or a placebo to see if it could quickly improve depression symptoms. The trial was completed and aimed to measure changes in mood using a standard depression scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AGN-241751 (an experimental oral drug for depression)
What this could lead to: If successful, this could point toward a new, fast-acting treatment option for people with major depressive disorder.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not confirm effectiveness or safety. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Alea Research

Phoenix, Arizona, 85012, United States
Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States
Collaborative Neuroscience Network, LLC

Garden Grove, California, 92845, United States
Hassman Research Institute

Berlin, New Jersey, 08809, United States
Northwest Clinical Research Center

Bellevue, Washington, 98007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.